- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Taglich Brothers, Inc. announces it initiated coverage of BioForce Nanosciences Holdings, Inc. (OTCBB: BFNH).
BioForce Nanosciences, headquartered in Ames, IA, markets the Nano eNabler(TM), a benchtop molecular printer used to produce ultraminiaturized biological sensors, biological tests and other ultraminiaturized devices. The company produces proprietary consumables -- surface patterning tools and silicon chips -- to support the Nano eNabler, and is developing advanced diagnostics, standard and customized patterned surfaces, a high-throughput Nano eNabler system for use by biopharmaceutical firms and a Nano eNabler for use specifically in cellular biology research.
The Nano eNabler system can be used in the production of ultraminiaturized biological sensors, biomedical tests and other ultraminiaturized devices that could fuel growth of nanotechnology and overcome limitations of existing technologies aimed at microscale encoding. Researchers and scientists seeking to perform takes at the nanoscale are likely to turn increasingly to systems such as the Nano eNabler for their instrumentation needs.
Beyond commercialization of the Nano eNabler in the academic research community, the company aims to pursue development of proprietary diagnostics, therapeutics, self-diagnosis systems, and, ultimately, capabilities for personalized medicine. The company also aims to commercialize, possibly by 2008, a high-throughput version of the Nano eNabler for production use in the biopharmaceutical industry. The ViriChip and nanodiagnostics, already in development, could be commercialized, respectively, by 2009 and 2010. Self-diagnosis and personalized medicine system are longer-term development projects.
The complete 18-page report is available at www.taglichbrothers.com.
About Taglich Brothers, Inc.
Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.
We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the Company mentioned in this report: All research issued by Taglich Brothers, Inc. is based on public information. In November 2007, the company paid a monetary fee of US$24,000 for the creation and dissemination of research reports for one year, and will, starting one year after the publication of an initial research report, pay a monetary fee of US$2,000 per month for the continued creation and dissemination of research reports.
For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.
For more information, please click here
Taglich Brothers, Inc.
Copyright © MarketwireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Clues to inner atomic life from subtle light-emission shifts: Hyperfine structure of light absorption by short-lived cadmium atom isotopes reveals characteristics of the nucleus that matter for high precision detection methods July 3rd, 2015